Podcast episode 144 (in German)
Acarbose – a diabetes drug from Kenya, a mouse record and a bagel test
November 21, 2026
Acarbose is an old diabetes drug produced by a bacterium from Kenya, and in the world’s strictest mouse program male animals lived 22 percent longer on it. The episode tells both halves of this story and asks what of it reaches the dinner table.
What it is about
In the small intestine, acarbose blunts the enzymes that break down starch and table sugar: the bread reaches the blood more slowly, and part of it travels into the large intestine, where it is fermented by bacteria. In Germany the drug has been approved since 1990 and is prescription-only. In the Interventions Testing Program it repeatedly extended the lives of male mice, much less so in females. People who want to live healthily for longer are already taking it today: one provider showed a flatter curve after eating in a small, self-funded pilot study with a glucose sensor and a bagel, and on a review portal users report bloating but mostly consider it worthwhile. What is established in humans is that acarbose delays diabetes in impaired glucose tolerance, but not that it protects the heart or extends life.
Key points
- In the mouse program in 2014, median lifespan rose by 22 percent in males and 5 percent in females; repeat studies yielded 16 to 17 and 4 to 5 percent, in males also when started after 16 months.
- At all 3 sites of the mouse program, a certain group of bacteria flourished under acarbose and more propionate was produced; the amount of such fermentation products in the feces helped predict lifespan.
- In a pilot study with 12 healthy adults, the sugar peak after a bagel with acarbose was more than 17 percent lower, without more complaints; the provider paid for it, and 4 authors work there.
- User reports, not statistics: on an American review portal, 5 of only 7 users gave 8 to 10 out of 10 points; bloating comes up again and again, and one writes that it eased over time.
- In STOP-NIDDM with 1,429 people with impaired glucose tolerance, there was around one quarter less diabetes in 2002; a post-hoc analysis reported 49 percent fewer cardiovascular events, with a very wide uncertainty range.
- The ACE trial in China tested the heart directly, with 6,522 people over an average of 5 years: hazard ratio 0.98, so no protection, but diabetes in 13 instead of 16 percent.
- In ACE, 7 percent on acarbose stopped or reduced it because of gastrointestinal complaints, 5 percent on placebo; the quality-of-life questionnaire collected over years showed no difference.
Where the data stop
Whether acarbose lets people live longer has never been measured. The only study on this, the Study of Acarbose in Longevity in people aged 60 and over, ended after 28 participants, according to the registry due to lack of funding. The mouse finding has been confirmed several times but applies mainly to males, as with most life-extending substances from the program; why is unclear. In humans, a small study found hardly any change in the gut after 2 weeks.
The flatter curve on the sensor is real pharmacology, but a first step, not proof of a longer life. The delay of diabetes lasts only as long as you take the drug; after stopping, new cases rose again. The benefit is established in impaired glucose tolerance, not in healthy people. Acarbose is prescription-only, so the question belongs in a doctor’s practice, together with a blood sugar value after eating. Anyone who has been prescribed it does not stop it on their own.
Listen (in German)
Listen on Spotify Listen on Apple Podcasts Listen on Amazon Music
Published on November 21, 2026.
The topic in the database
- Old diabetes drug with a longevity bonus: slows the absorption of sugar from starch – and in the large US aging program (ITP) extended the lif…Acarbose
All episodes in the app (German)
Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in the hands of a physician. Last updated: 2026-09-25.